HRP20220029T1 - Supstituirani derivati ksantina - Google Patents

Supstituirani derivati ksantina Download PDF

Info

Publication number
HRP20220029T1
HRP20220029T1 HRP20220029TT HRP20220029T HRP20220029T1 HR P20220029 T1 HRP20220029 T1 HR P20220029T1 HR P20220029T T HRP20220029T T HR P20220029TT HR P20220029 T HRP20220029 T HR P20220029T HR P20220029 T1 HRP20220029 T1 HR P20220029T1
Authority
HR
Croatia
Prior art keywords
image
compound according
disorder
disorders
disease
Prior art date
Application number
HRP20220029TT
Other languages
English (en)
Croatian (hr)
Inventor
Kai Gerlach
Christian Eickmeier
Achim Sauer
Stefan Just
Bertrand L. Chenard
Original Assignee
Boehringer Ingelheim International Gmbh
Hydra Biosciences, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh, Hydra Biosciences, Llc filed Critical Boehringer Ingelheim International Gmbh
Publication of HRP20220029T1 publication Critical patent/HRP20220029T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HRP20220029TT 2017-07-11 2018-07-06 Supstituirani derivati ksantina HRP20220029T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17180721 2017-07-11
EP18735588.8A EP3652176B1 (en) 2017-07-11 2018-07-06 Substituted xanthine derivatives
PCT/EP2018/068366 WO2019011802A1 (en) 2017-07-11 2018-07-06 NEW SUBSTITUTED XANTHINE DERIVATIVES

Publications (1)

Publication Number Publication Date
HRP20220029T1 true HRP20220029T1 (hr) 2022-04-15

Family

ID=59325162

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20220029TT HRP20220029T1 (hr) 2017-07-11 2018-07-06 Supstituirani derivati ksantina

Country Status (32)

Country Link
US (1) US10329292B2 (cg-RX-API-DMAC7.html)
EP (1) EP3652176B1 (cg-RX-API-DMAC7.html)
JP (1) JP7114702B2 (cg-RX-API-DMAC7.html)
KR (1) KR102714554B1 (cg-RX-API-DMAC7.html)
CN (1) CN110997675B (cg-RX-API-DMAC7.html)
AR (1) AR112448A1 (cg-RX-API-DMAC7.html)
AU (1) AU2018299824B2 (cg-RX-API-DMAC7.html)
CA (1) CA3066922A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020000056A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019015102A2 (cg-RX-API-DMAC7.html)
CY (1) CY1125014T1 (cg-RX-API-DMAC7.html)
DK (1) DK3652176T3 (cg-RX-API-DMAC7.html)
EA (1) EA039526B1 (cg-RX-API-DMAC7.html)
ES (1) ES2903268T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20220029T1 (cg-RX-API-DMAC7.html)
HU (1) HUE057600T2 (cg-RX-API-DMAC7.html)
IL (1) IL271799B (cg-RX-API-DMAC7.html)
LT (1) LT3652176T (cg-RX-API-DMAC7.html)
MX (1) MX394089B (cg-RX-API-DMAC7.html)
MY (1) MY200797A (cg-RX-API-DMAC7.html)
PE (1) PE20200861A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020500079A1 (cg-RX-API-DMAC7.html)
PL (1) PL3652176T3 (cg-RX-API-DMAC7.html)
PT (1) PT3652176T (cg-RX-API-DMAC7.html)
RS (1) RS62826B1 (cg-RX-API-DMAC7.html)
SA (1) SA519410851B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201912168TA (cg-RX-API-DMAC7.html)
SI (1) SI3652176T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202200013T1 (cg-RX-API-DMAC7.html)
TW (1) TWI801398B (cg-RX-API-DMAC7.html)
UA (1) UA124793C2 (cg-RX-API-DMAC7.html)
WO (1) WO2019011802A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019231208B2 (en) * 2018-03-05 2025-01-23 Gfb (Abc), Llc Imidazodiazepinediones and methods of use thereof
US12291532B2 (en) 2018-12-12 2025-05-06 Boehringer Ingelheim International Gmbh Substituted xanthines as modulators of TRPC5 activity
IL283768B2 (en) * 2018-12-12 2024-05-01 Boehringer Ingelheim Int Xanthine histories are transmuted
AU2020357178A1 (en) * 2019-10-04 2022-05-12 Gfb (Abc), Llc Biomarker-based treatment of focal segmental glomerulosclerosis and diabetic kidney disease
CN118373832B (zh) * 2023-01-20 2025-01-28 深圳晶蛋生物医药科技有限公司 大环类化合物、其药物组合物及其应用
KR20250141831A (ko) 2023-02-08 2025-09-29 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 잔틴계 화합물 및 이의 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1953162T1 (sl) * 2001-02-24 2012-09-28 Boehringer Ingelheim Pharma Ksantinski derivati, njihova priprava in njihova uporaba kot zdravila
US6869947B2 (en) * 2001-07-03 2005-03-22 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
ATE496894T1 (de) * 2006-07-14 2011-02-15 Pfizer Prod Inc Tartratsalz von (7s)-7-ä(5-fluor-2-
MX370372B (es) * 2013-03-15 2019-12-11 Hydra Biosciences Inc Xantinas sustituidas y metodos de uso de las mismas.
TWI676626B (zh) * 2014-04-23 2019-11-11 美商美國禮來大藥廠 抑制瞬時受體電位a1離子通道
EP3180340B1 (en) * 2014-08-11 2018-10-10 Hydra Biosciences, Inc. Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives
JP6667092B2 (ja) * 2014-08-11 2020-03-18 ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーHydra Biosciences, LLC ピロロ[3,2−d]ピリミジン−2,4(3H,5H)−ジオン誘導体
EP3194367B1 (en) 2014-09-17 2021-08-18 Boehringer Ingelheim International GmbH Tetrahydroisoquinoline derivatives and pharmaceutical compositions useful for the treatment of obesity and diabetes

Also Published As

Publication number Publication date
EP3652176A1 (en) 2020-05-20
PT3652176T (pt) 2022-01-13
US20190016722A1 (en) 2019-01-17
EA039526B1 (ru) 2022-02-07
PE20200861A1 (es) 2020-08-25
TWI801398B (zh) 2023-05-11
KR20200030048A (ko) 2020-03-19
CO2019015102A2 (es) 2020-05-15
BR112019025611A2 (pt) 2020-06-16
EP3652176B1 (en) 2021-12-15
HUE057600T2 (hu) 2022-05-28
SI3652176T1 (sl) 2022-04-29
US10329292B2 (en) 2019-06-25
CN110997675A (zh) 2020-04-10
AR112448A1 (es) 2019-10-30
JP7114702B2 (ja) 2022-08-08
RS62826B1 (sr) 2022-02-28
MY200797A (en) 2024-01-16
SA519410851B1 (ar) 2023-02-26
PL3652176T3 (pl) 2022-04-04
WO2019011802A1 (en) 2019-01-17
UA124793C2 (uk) 2021-11-17
DK3652176T3 (da) 2022-01-17
PH12020500079A1 (en) 2020-10-05
SMT202200013T1 (it) 2022-03-21
MX2020000402A (es) 2020-08-17
CL2020000056A1 (es) 2020-06-12
EA202090270A1 (ru) 2020-04-24
LT3652176T (lt) 2022-02-25
CA3066922A1 (en) 2019-01-17
KR102714554B1 (ko) 2024-10-10
CY1125014T1 (el) 2023-03-24
ES2903268T3 (es) 2022-03-31
AU2018299824B2 (en) 2022-06-16
CN110997675B (zh) 2022-06-07
MX394089B (es) 2025-03-24
IL271799A (en) 2020-02-27
JP2020526591A (ja) 2020-08-31
AU2018299824A1 (en) 2019-12-19
NZ759728A (en) 2024-11-29
IL271799B (en) 2022-08-01
SG11201912168TA (en) 2020-01-30
TW201908318A (zh) 2019-03-01

Similar Documents

Publication Publication Date Title
BR112018000041A2 (pt) Derivados de carbamato de 1,1,1-trifluoro-3- hidroxipropan-2-ila e derivados de carbamato de 1,1,1-trifluoro-4-hidroxibutan-2-ila como inibidores de magl
Kaufmann et al. NLRP3 inflammasome-driven pathways in depression: clinical and preclinical findings
CO2019006785A2 (es) Inhibidores biciclo[1.1.1]pentano de la cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades
JP2019524822A5 (cg-RX-API-DMAC7.html)
Landelle et al. Functional brain changes in the elderly for the perception of hand movements: A greater impairment occurs in proprioception than touch
MA50763A (fr) Compositions d'acides aminés et méthodés de traitement de maladies et troubles musculaires
EA201990450A1 (ru) Ингибиторы киназы, содержащей домен с двумя лейциновыми "застежками-молниями" (dlk), для лечения заболевания
BR112017022568A2 (pt) compostos e seus usos como inibidores de bace1
WO2016024205A8 (en) Oligomers targeting hexanucleotide repeat expansion in human c9orf72 gene
HRP20251221T1 (hr) Neuroaktivni steroidi i postupci za njihovu uporabu
WO2018060732A3 (en) Compositions and methods for treating seizure disorders
ME02390B (me) Inhibitori beta sekretaze
JP2020526591A5 (cg-RX-API-DMAC7.html)
HUE073599T2 (hu) Módosított aminosav-származékok neurológiai betegségek és kiválasztott pszichiátriai rendellenességek kezelésére
MY189740A (en) Butylphthalide-telmisartan heterocomplex, preparation method and application thereof
EP3581175A4 (en) PREPARATION FOR THE ADMINISTRATION OF A DRUG FOR THE TREATMENT OF MENTAL ILLNESSES OR CENTRAL NERVOUS SYSTEM DISORDERS
WO2007135131A8 (en) Substituted pyrazinone derivatives for use as a medicine
ATE457985T1 (de) Substituierte pyrazinonderivate zur verwendung als arzneimittel
HRP20260264T1 (hr) Kanabinoidni pripravak i njegova primjena u pripremi lijeka za liječenje neurodegenerativnih bolesti kao što su parkinsonova bolest i alzheimerova bolest
AR112472A1 (es) Forma de sales cristalinas de amida de levodopa y métodos para elaborarlas y usarlas
AR121118A1 (es) Factores de transcripción de proteínas de dedos de zinc para reprimir la expresión de tau
WO2020123977A3 (en) Glial fibrillary acidic protein targeting immuno-and aptamer-based-therapy for neuroinjury, neurodegeneration, neuro-disease, and neuro-repair
WO2018027037A3 (en) Reelin compositions for treatment of neurological disorders
ATE471322T1 (de) Substituierte pyrazinonderivate zur verwendung als arzneimittel
JP2017525776A5 (cg-RX-API-DMAC7.html)